In December 2024, a 21-year-old man from New York received groundbreaking treatment for sickle cell anemia using Lyfgenia, a revolutionary gene therapy developed by Bluebird Bio. This treatment has not only cured this man of his sickle cell anemia, but it has offered hope to countless others suffering from this debilitating, often-overlooked disease. Yet, despite its success, the cost of this treatment remains impossibly expensive for most people who desperately need it.
Sign the petition to demand that Bluebird Bio lower the price of Lyfgenia to make this potentially life-saving treatment accessible to all who need it!
Sickle cell anemia, which primarily affects Black and Hispanic communities, is a serious and inherited blood disorder that causes severe pain, organ damage, and a significantly reduced life expectancy. The fact that a cure is now available should be celebrated, but the $3.1 million price tag for Lyfgenia raises serious concerns about how many people will actually be able to afford this treatment.
The solution is clear: the price must be lowered so that more people can access the treatment. The U.S. healthcare system needs to ensure that life-saving medications are available to everyone, not just the privileged few who can afford astronomical prices.
We call on Bluebird Bio to take immediate action by significantly reducing the cost of Lyfgenia and making it available to those who need it most, regardless of their ability to pay. In addition, we urge the FDA and Health and Human Services to help make this treatment affordable and accessible for all sickle cell patients across the U.S.
Sign the petition now to demand that Bluebird Bio make a fair and just decision for the future of sickle cell patients!
